Breast Cancer Coverage from Every Angle

Julia Tchou, MD, PhD, on Clinical Implications of Combining a Radiation Boost and Pembrolizumab in Triple-Negative Breast Cancer

Posted: Friday, December 2, 2022

Julia Tchou, MD, PhD, of the University of Pennsylvania, discusses results of the phase Ib/II BreastVax study, which suggested that combining radiotherapy with immune checkpoint inhibition in the form of a single neoadjuvant dose of pembrolizumab may result in pathologic response in patients with early-stage triple-negative breast cancer. This approach may help select patients as candidates for chemotherapy omission.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.